Early blood markers may spot gestational diabetes risk

NCT ID NCT05632055

Ongoing Knowledge-focused Sponsor: Chiang Mai University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study in Thailand is testing whether two substances in the blood (miRNA and FGF21) measured during the first trimester can predict which women will develop gestational diabetes later in pregnancy. Researchers will compare levels between 160 women who do and do not develop the condition. If the markers prove reliable, it could lead to earlier screening and better outcomes for mothers and babies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test early in pregnancy to identify women at risk for gestational diabetes, allowing earlier monitoring and care.
What could go wrong: This is an observational study, not a treatment trial. The markers may not prove accurate enough for routine use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GESTATIONAL DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gestational diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GESTATIONAL DIABETES

Contacts and locations

Locations

Maharaj Nakorn ChiangMai Hospital

Chiang Mai, ChiangMai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.